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Abstract We present a rat model in which continuous supply of
hepatocyte growth factor (HGF) prevents liver injury induced by
carbon tetrachloride (CCl
4
) and E. coli 011:B4 lipopolysacchar-
ide (LPS). Rat fibroblasts genetically modified to secrete rat
HGF were implanted in syngenic rat spleen 7 days before
administration of the hepatotoxins. Rats with HGF-secreting
fibroblasts in the spleen showed a dramatic resistance to CCl
4
-
and LPS-induced liver injury. In the LPS-induced liver injury
model, blood chemical analysis revealed that the increase in
serum glutamic oxalacetic transaminase level and the decrease in
blood sugar level were remarkably suppressed in rats with HGF-
secreting cells in the spleen. Most importantly, their survival rate
was greatly improved compared to other control groups of rats.
Thus our results indicate a new role of HGF in liver protection
during endotoxemia and convey important clinical implications
for developing new therapeutic modalities in the treatment of
liver failure caused by endotoxemia.
z 1997 Federation of European Biochemical Societies.
Key words: Hepatocyte growth factor; CCl
4
; Endotoxin;
Liver injury; Protection
1. Introduction
Despite remarkable advances in chemotherapeutic and sup-
porting agents, organ injury induced by septic syndrome due
to Gram-negative bacteremia or endotoxemia is still one of
the most threatening complications that follow trauma, burn
and many types of surgery. The septic syndrome a¡ects the
lungs, liver, heart, kidneys, and gastrointestinal tract, fre-
quently leading to multiple organ failure and produces high
rates of morbidity and mortality [1,2]. Gram-negative bacte-
rial lipopolysaccharide (LPS) is thought to mediate many
pathophysiological manifestations of this syndrome. Although
experimental animal models have provided the framework for
the knowledge of the mechanisms of organ injury induced by
LPS [3], an e¡ective therapeutic approach remains to be es-
tablished.
Development of cytokine therapy has greatly facilitated
treatment of patients in various situations [4^8], while for
organ injury induced by endotoxemia, successful treatment
by cytokine has not been reported. Since most of the cyto-
kines have rather short half-lives in vivo, continuous admin-
istration of recombinant products by use of pumps or repet-
itive injections have been employed to provide sustained
serum level of a cytokine [9^11]. Another attractive way of
continuous cytokine supply would be implantation of autolo-
gous or syngenic cells genetically modi¢ed to secrete recombi-
nant product. Indeed, such cells have been shown to be of
great advantage to therapy in animal models. Rosenthal et al.
demonstrated that granulocyte-macrophage colony-stimulat-
ing factor-secreting, irradiated syngenic murine cells accelerate
hematopoietic recovery after cytotoxic chemotherapy [12]. Re-
cently, Moullier et al. reported that intraperitoneally im-
planted collagen lattices containing genetically modi¢ed autol-
ogous ¢broblasts show a sustained secretion of human L-
glucuronidase in dogs [13].
Hepatocyte growth factor (HGF) was originally found in
the serum of partially hepatectomized rat [14] and in rat plate-
lets [15] as the most potent stimulator of hepatocyte growth
and DNA synthesis in vitro [16,17]. Recent reports showed
that intravenous injection of puri¢ed human recombinant
HGF (rHGF) enhanced liver or renal regeneration in mice
[18,19], prevented acute renal failure [19] and suppressed the
onset of liver cirrhosis induced by dimethylnitrosamine [20],
suggesting that HGF may play important roles in the tissue
repair process. We generated genetically modi¢ed syngenic
cells to supply rHGF to the liver and demonstrate for the ¢rst
time that continuous rHGF supply can successfully prevent
LPS-induced liver injury in rats.
2. Materials and methods
2.1. Animals
Male F344 rats weighing 200^250 g (SRL, Hamamatsu, Japan)
were used. All animals received humane care. A nutritionally balanced
rodent diet and water were provided ad libitum.
2.2. Plasmids
Rat HGF cDNA [21] was inserted into the unique BamHI site of
the pCMV-Neo-Bam vector [22] to generate a rat HGF expression
vector, pCMV/HGF.
2.3. Cells and transfection
One day before transfection, approximately 2U10
5
of Rat-1 cells
[23], immortalized but not tumorigenic F344 rat-derived ¢broblasts,
were plated into a 6.0 cm dish with Dulbecco's modi¢ed Eagle's me-
dium (DMEM) (Nissui, Tokyo, Japan) containing 10% fetal calf se-
rum (GIBCO, BRL, USA), penicillin (50 U/ml) and streptomycin (50
Wg/ml) (standard medium). Rat-1 cells were transfected either with
2 Wg of pCMV/HGF or 2 Wg of pCMV-Neo-Bam plasmid DNA by
the calcium phosphate method [24]. Transfectants were subjected to
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selection with 500 Wg/ml of G418 (GIBCO, BRL, USA) and resultant
G418-resistant colonies were either isolated, colony by colony, using a
stainless-steel cylinder for rHGF-secreting cells or trypsinized and
pooled for control cells.
2.4. ELISA assay and bioassay of rHGF
Conditioned medium derived from each established cell line was
collected from con£uent cultures. Portal blood was collected 7 days
after cell implantation. HGF concentrations in conditioned medium
or plasma from portal blood were measured using an enzyme-linked
immunosorbent assay (ELISA) kit (Institute of immunology, Tokyo,
Japan). Biological activity of the rHGF was determined by BrdU
staining of hepatocytes in primary culture as described previously [25].
2.5. Cell implantation
Rat-1/CMV cells or Rat-1/rat HGF3 cells (W3U10
6
cells) sus-
pended in 0.1 ml of DMEM were injected into the spleen of F344
rats through a 26 G needle. The injection site on the surface of the
spleen was immediately ligated to minimize leakage of implanted cells.
To examine the deteriorative e¡ects on the delivery of HGF by sys-
temic circulation and the local connective tissue, we also implanted
Rat-1/rat HGF3 cells (W6U10
6
cells) into the subcutaneous tissue of
the upper back of rats.
2.6. Assessment of liver injury
Seven days after ¢broblast implantation, CCl
4
(Wako, Osaka, Ja-
pan) dissolved in olive oil was intraperitoneally injected at a dose of
1.5 ml/kg body weight. Forty-eight hours after CCl
4
injection, the
animals were killed and blood was collected from the aorta. Immedi-
ately after blood collection, each liver was removed for histochemical
study (hematoxylin and eosin staining; HE staining) to observe his-
tological change. To evaluate quantitatively the degree of liver injury
after CCl
4
administration, the levels of serum glutamic oxalacetic
transaminase (GOT) and glutamic pyruvic transaminase (GPT) were
measured with an autoanalyzer. LPS from E. coli 011:B4 (DIFCO,
Detroit, MI) (16 mg/kg body weight) dissolved in saline was intra-
venously injected 7 days after cell implantation. The animals were
killed 6 h after LPS injection to evaluate the degree of liver injury
in acute endotoxemia [26]. Rats were also examined before LPS treat-
ment. The amounts of serum GOT, GPT, and blood sugar (BS) were
measured with an autoanalyzer. The survival of rats was determined
48 h after LPS injection.
2.7. Statistical evaluation
Results are expressed as mean þ SD. Student's t-test was used to
compare the mean values of the groups.
3. Results
3.1. Establishment of cell lines stably secreting rat rHGF
We established clonal cell lines secreting rat rHGF by trans-
fection of Rat-1 cells with a HGF-expression vector, whose
HGF production was determined by ELISA. As a control,
Rat-1 cells transfected with the vector plasmid alone, selected
and pooled were designated as Rat-1/CMV cells. HGF was
barely detectable in conditioned medium prepared from con-
trol cells, while the clonal cell lines were found to produce
large amounts of HGF. One of the established cell clones,
Rat-1/rat HGF3 cell line was used in the following experi-
ments, which produces the largest amount of rHGF
at a rate of approximately 75 ng per 10
6
cells per 24 h.
The secreted rHGF was con¢rmed to be biologically
active on rat hepatocytes in primary culture. The labeling
index of hepatocytes alone, hepatocytes provided with condi-
tioned medium from Rat-1/CMV cells or Rat-1/rat HGF3
cells was 0.6%, 0.8% and 23.8%, respectively, indicating
that rHGF produced by Rat-1/rat HGF3 cells serves as a
biologically potent mitogen for rat hepatocytes in primary
culture.
3.2. E¡ects of rHGF on CCl
4
-induced acute liver injury
To con¢rm the biological activity of secreted rat rHGF in
vivo, we tested its protective e¡ect on CCl
4
-induced hepato-
cyte injury in the rat model we previously reported for human
rHGF. Production of rHGF by the implanted cells was veri-
¢ed by measuring the concentration of HGF in the portal
blood (Table 1). The mean HGF concentration in the portal
blood 7 days after cell implantation, when implanted cells are
found to secret rHGF stably, was 2.0þ 0.8 ng/ml in rats with
Rat-1/rat HGF3 cells in the spleen, while it was under detect-
able level (6 0.1 ng/ml) in rats with Rat-1/CMV cells. Histo-
logical examination at 48 h after CCl
4
injection revealed that
hepatocytes around the central veins were necrotic in rats
implanted with Rat-1/CMV cells. However, necrosis was
barely detectable in the liver of rats with Rat-1/rat HGF3 cells
in the spleen. Fig. 1 shows that these histological ¢ndings
correlated well with biochemical data that the increase in se-
rum GOT and GPT levels caused by CCl
4
administration was
markedly suppressed by implantation of Rat-1/rat HGF3 cells
in the spleen (P6 0.001). As compared with our earlier results
with human rHGF [25], syngenic rHGF has proved to be
more e¡ective probably because of the absence of neutralizing
antibody production in vivo.
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Table 1
HGF concentration in the portal blood was determined by ELISA
assay 7 days after cell implantation
Group HGF concentration
(ng/ml)
Rat-1/CMV (spleen) 6 0.1
Rat-1/rat HGF3 (spleen) 2.0þ 0.8

Rat-1/rat HGF3 (subcutaneous) 6 0.1

P6 0.001 vs. control.
Fig. 1. Serum GOT and GPT levels 48 h after CCl
4
injection in
rats implanted with Rat-1/CMV cells (white bars) or with Rat-1/rat
HGF3 cells in the spleen (shaded bars).
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3.3. Implantation of Rat-1/rat HGF3 cells in the spleen
prevents LPS-induced liver injury
We next analyzed the e¡ect of rHGF supply on LPS-in-
duced liver injury in the same rat model. Liver specimens
taken from control rats 6 h after LPS challenge exhibited
massive hepatocellular necrosis and ¢brin deposition in portal
veins, which were blocked almost completely by rHGF treat-
ment (Fig. 2). The levels of GOT, GPT, and BS before LPS
injection in rats implanted with Rat-1/rat HGF3 cells were not
signi¢cantly di¡erent from those in control rats with Rat-1/
CMV cells (Fig. 3). Six hours after LPS injection, the increase
in serum GOT and GPT level was much reduced in rats
with Rat-1/rat HGF3 cells (54þ 7C486þ 132 IU/l,
48þ 8C303þ124 IU/l, respectively) compared with that in
control rats (53 þ 6C1809þ 339 IU/l, 46 þ 7C1382þ 229
IU/l, respectively) (P6 0.001). Similarly, severe hypoglycemia
observed in control rats (167þ 23C72þ 8 mg/dl) was virtually
prevented in rats with Rat-1/rat HGF3 cells in the spleen
(170þ 18C127þ 13 mg/dl) (P6 0.001). Implantation of Rat-
1/rat HGF3 cells in the truncal subcutaneous tissue did not
prevent the increase in the transaminase levels nor the severe
hypoglycemia during acute endotoxemia. This can be ex-
plained by the fact that the mean HGF concentration in the
portal blood 7 days after subcutaneous cell implantation was
under detectable level (6 0.1 ng/ml) (Table 1). Importantly, at
48 h after LPS injection, 8 of 10 rats with Rat-1/rat HGF3
cells in the spleen survived whereas 2 of 10 rats with Rat-1/
CMV cells in the spleen and 1 of 5 rats with Rat-1/rat HGF3
cells in the subcutaneous tissue were alive, indicating a crucial
role of rHGF provided from ¢broblasts implanted in the
spleen (Table 2). In each group, most of the rats which could
not survive were dead within 12 h after LPS injection, suggest-
ing that the direct cause of the death is more likely LPS-
induced endotoxin shock rather than liver failure.
4. Discussion
This report demonstrates that continuous and direct supply
of rHGF to the liver represents a successful approach for
prevention of liver failure caused by endotoxemia. The liver
is a major organ for LPS detoxi¢cation during endotoxemia
[27]. This process is accompanied by hepatocellular damage
being initiated by the LPS-induced activation of phagocytic
cells such as polymorphonuclear neutrophils and Kup¡er cells
which produce excess in£ammatory cytokines and toxic chem-
ical mediators including tumor necrosis factor-K (TNF-K) and
interleukin-1 (IL-1) [28,29]. In our model, however, it is not
likely that rHGF directly modulated the activity of the hepatic
macrophages since they are reported to lack HGF receptor
expression [30]. While it has been reported that activated hep-
atic macrophages or neutrophils are mainly responsible for
LPS-induced hepatocyte injury in vivo [3,29], CCl
4
is reported
not to primarily activate phagocytic cells in the liver, but
rather directly damage hepatocytes by oxidative stress [31].
Although recent reports have suggested possible involvement
of TNF-K in the pathogenesis of CCl
4
-induced hepatocyte
necrosis [32,33], it is likely that the e¡ects of hepatoxins on
RNA and protein synthesis render normal hepatocytes suscep-
tible to additional cytotoxicity from TNF-K as mentioned by
Czaja et al. [32]. Thus HGF protects the liver from the two
di¡erent types of injury, suggesting that it eventually protects
hepatocytes directly or by interfering with the processes com-
mon to these types of liver injury.
On the other hand, since HGF a¡ects a variety of epithelial
and endothelial cells in their behavior, it is reasonable to
assume that the exogenous HGF might have contributed to
maintaining fundamental functions of other vital organs such
as the lungs and heart during acute endotoxemia. The fact
that most of rats which could not survive 48 h after LPS
challenge were dead within early time points suggests that
the direct cause of death might be rather LPS-induced endo-
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Fig. 2. HE staining of rat liver 6 h after LPS injection from rats implanted with Rat-1/CMV cells (A) or with Rat-1/rat HGF3 cells (B) in the
spleen (U350). The arrow and arrowhead in (A) indicate massive hepatocellular necrosis and ¢brin deposition in portal vein, respectively.
Table 2
HGF supply from the spleen improves survival of rats in acute en-
dotoxemia
Group Survival rate P value
(vs. Rat-1/CMV)
Rat-1/CMV (spleen) 2/10 (20%) 3
Rat-1/rat HGF3 (spleen) 8/10 (80%) 6 0.01
Rat-1/rat HGF3 (subcutaneous) 1/5 (20%) NS
Seven days after ¢broblast implantation, LPS from E. coli 011:B4
(DIFCO, Detroit, MI) (16 mg/kg body weight) dissolved in saline
was intravenously injected. The survival of rats was determined 48
h after LPS injection.
NS: not signi¢cant.
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toxin shock than liver failure. We suppose that HGF might
have not only cytoprotective e¡ect for the liver but also anti-
shock ability. We are currently investigating the e¡ects of the
rHGF on general circulation, renal and pulmonary functions
as well as on hepatic sinusoidal cells in the same model.
A variety of animal models have been reported for the
treatment of acute endotoxemia [34^38], most of which have
focused on targeting bacterial products or suppression of cas-
cades of immunologic and in£ammatory events. However,
attempts to protect targeted host organs from tissue injury
during endotoxemia seem not yet to have been made exten-
sively. We employed a new method of HGF supply for the
following reasons. Firstly, since puri¢ed recombinant rat
HGF protein is not currently available, cells genetically modi-
¢ed to secrete rat rHGF were used in this study to avoid
neutralizing antibody production. Secondly, HGF de novo
synthesized in the spleen would hardly disperse or lose its
activity before reaching the liver as we implanted Rat-1/rat
HGF3 cells in the organ directly upstream of the liver.
Thirdly, the spleen may provide a desirable environment for
implanted Rat-1/rat HGF3 cells to supply HGF instantly as it
is rich in blood vessels. It awaits further investigation how
rHGF a¡ects the usual cytokine production in the spleen.
Finally, as is thought to be the most important advantage,
HGF could be continuously supplied throughout the entire
course of the experiment. It is reported that the half-life
time for HGF administered intravenously is less than 5 min
[39]. While CCl
4
administration is known to cause liver injury
as well as subsequent elevation of plasma HGF concentration
over 100 ng/ml [40] which by far exceeds that of HGF pre-
sented in our model, we suppose that it is rHGF continuously
supplied from the spleen that might keep targeted cells, in-
cluding hepatocytes, in a primed state resulting in marked
resistance against the hepatotoxins.
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Fig. 3. The e¡ects of HGF secreted from implanted ¢broblasts on LPS-induced endotoxin shock. Serum GOT (A), GPT (B), and BS (C) levels
of rats implanted with Rat-1/CMV cells (a) or with Rat-1/rat HGF3 cells in the spleen (b) were measured before or 6 h after LPS injection.
Those in rats implanted with Rat-1/rat HGF3 cells in the subcutaneous tissue (E) were measured 6 h after LPS injection.
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Our results would convey important clinical implications.
Firstly, the spleen represents a suitable organ where geneti-
cally modi¢ed cells are implanted to provide recombinant
products directly to the liver. Secondly, if one should view
surgery as a `planned wounding', it is tempting to speculate
that pre-operative HGF supply could prevent liver failure
caused by severe endotoxemia after major surgery including
extended hepatectomy. Finally, given the role of HGF in pro-
moting the integrity of hepatocytes as well as their survival, its
continuous supply might ameliorate or arrest progression of
chronic hepatic disorders. Thus, continuous delivery of rHGF
would have a great deal of potential for prevention and treat-
ment of liver diseases.
In conclusion, we presented clear evidences of successful
liver protection from LPS-induced injury by rHGF although
its clinical application requires further development of meth-
ods for practical supply of this cytokine.
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